New Jersey 2022-2023 Regular Session

New Jersey Assembly Bill A2336

Introduced
2/7/22  

Caption

Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

Impact

The establishment of the commission is expected to have significant implications for state law, particularly in how pharmaceutical manufacturing is regulated. By centralizing the oversight of API manufacturing, the commission seeks to promote growth in this sector, potentially attracting more business and investment into New Jersey. This could lead to an increase in both job opportunities and the state's economic growth in the pharmaceutical realm, particularly as the market for APIs continues to expand given increasing demand from companies both within and outside the state.

Summary

Assembly Bill A2336 aims to establish the New Jersey Active Pharmaceutical Ingredient Regulatory Commission, which will play a critical role in overseeing the production and regulation of active pharmaceutical ingredients (APIs) within the state. This bill seeks to set standardized protocols for the manufacturing processes of APIs, ensuring that they adhere to both state and federal laws. By creating this commission, New Jersey positions itself as a leader in the pharmaceutical manufacturing industry while enhancing the oversight needed to ensure product quality and safety for consumers.

Contention

There are likely to be areas of contention surrounding the bill, particularly regarding the appointment process for commission members and the commission's independence from other governmental entities. The bill mandates that public members should come from diverse backgrounds to ensure that multiple perspectives are represented; however, the success of this initiative ultimately hinges on the fair and transparent selection of these appointees. Critics may also voice concerns over the commission's potential authority over established businesses and practices, leading to discussions about the balance between regulatory oversight and economic growth.

Companion Bills

No companion bills found.

Similar Bills

NJ A1838

Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

NJ S1161

Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

VA HB287

Cannabis; replaces the term "marijuana" throughout the Cannabis Control Act.

VA HB698

Cannabis control; establishes a framework for creation of a retail marijuana market, penalties.

VA HB1846

Medical marijuana program; product, registration, dispensing, and recordkeeping requirements.

VA SB1337

Medical marijuana program; product, registration, dispensing, and recordkeeping requirements.

VA SB423

Cannabis control; retail market, penalties.

VA SB1133

Cannabis control; retail market, transitional sales, regulated hemp products, penalties.